Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 6/20 | 0.49 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.47 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509611 | 0.91 | MME (0.53) | MAPK1CYP3A4MMEACEKMT2A | |
| SCHEMBL8820357 | 0.85 | MAPK1 (0.51) | MAPK1CYP3A4MMEKMT2AMEN1 | |
| SCHEMBL3256421 | 0.84 | MME (0.47) | MAPK1CYP3A4MMEACEKMT2A | |
| SCHEMBL7041284 | 0.79 | SIGMAR1 (0.55) | MAPK1CYP3A4KMT2AMEN1MAPT | |
| SCHEMBL1823141 | 0.79 | SIGMAR1 (0.55) | MAPK1CYP3A4KMT2AMEN1MAPT | |
| SCHEMBL23023068 | 0.79 | SIGMAR1 (0.55) | MAPK1CYP3A4KMT2AMEN1MAPT | |
| SCHEMBL10950036 | 0.79 | MME (0.43) | MAPK1MMEACEKMT2AALDH1A1 | |
| SCHEMBL7348151 | 0.78 | MAPK1 (0.58) | MAPK1CYP3A4MMEKMT2AMEN1 | |
| SCHEMBL7345520 | 0.78 | MAPK1 (0.58) | MAPK1CYP3A4MMEKMT2AMEN1 | |
| SCHEMBL3897966 | 0.78 | MAPK1 (0.68) | MAPK1CYP3A4MMEKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | CHONG, HYUN-SOON, PHD | 2017-01-12 | — | — | US | disclosed |
| WO-2010011367-A2 | BIMODAL LIGANDS WITH MACROCYCLIC AND ACYCLIC BINDING MOIETIES, COMPLEXES AND COMPOSITIONS THEREOF, AND METHODS OF USING | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008863-A1 | SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS | AZI2, ABL1, DHPS | MAPK1 4226/4885CYP3A4 142/4885MME 1541/4885 |
| US-10189803-B2 | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions | AZI2, ABL1, DHPS | MAPK1 4226/4885CYP3A4 142/4885MME 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.